Investor CF Woodford Equity Income Fund
13D/G Filings

This page shows a list of all the recent 13D/G filings made by CF Woodford Equity Income Fund . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2019-10-09 13G/A AUTL / Autolus Therapeutics plc - Depositary Receipt (Common Stock) 6,312,380 0
2019-09-09 13G/A PRTA / Prothena Corporation plc 7,948,790 0
2019-08-08 13G/A EVFM / Evofem Biosciences, Inc. 10,046,216 9,138,504
2019-05-10 13G/A EVFM / Evofem Biosciences, Inc. 9,138,504 10,046,216
2019-02-14 13G/A TBPH / Theravance Biopharma, Inc. 8,114,946 10,592,189
2019-02-14 13G/A NWBO / Northwest Biotherapeutics, Inc. 18,316,679 18,316,679
2019-02-14 13G/A PRTA / Prothena Corporation plc 7,684,790 7,948,790
2019-02-14 13G/A AUTL / Autolus Therapeutics plc - Depositary Receipt (Common Stock) 5,417,558 6,312,380
2018-12-10 13G/A EVFM / Evofem Biosciences, Inc. 7,663,504 9,138,504
2018-09-13 13G/A AUTL / Autolus Therapeutics plc - Depositary Receipt (Common Stock) 2,755,315 5,417,558
2018-07-10 13G AUTL / Autolus Therapeutics plc - Depositary Receipt (Common Stock) 2,755,315
2018-06-11 13G EVFM / Evofem Biosciences, Inc. 7,663,504
2018-02-13 13G/A PRTA / Prothena Corporation plc 6,869,266 7,684,790
2018-02-13 13G/A TBPH / Theravance Biopharma, Inc. 8,365,839 8,114,946
2018-02-13 13G/A NWBO / Northwest Biotherapeutics, Inc. 18,316,679 18,316,679
2017-09-11 13G/A NWBO / Northwest Biotherapeutics, Inc. 18,316,679 18,316,679
2017-02-14 13G/A PRTA / Prothena Corporation plc 4,934,266 6,869,266
2017-02-14 13G/A TBPH / Theravance Biopharma, Inc. 4,744,076 8,365,839
2017-01-10 13G/A NWBO / Northwest Biotherapeutics, Inc. 14,280,316 18,316,679
2016-02-19 13G/A TBPH / Theravance Biopharma, Inc. 3,968,790 4,744,076
2016-02-19 13G/A PRTA / Prothena Corporation plc 3,022,222 4,934,266
2015-11-10 13G TBPH / Theravance Biopharma, Inc. 3,968,790
2015-09-09 13G/A NWBO / Northwest Biotherapeutics, Inc. 6,342,621 14,280,316
2015-04-07 13G NWBO / Northwest Biotherapeutics, Inc. 6,342,621
2015-04-07 13G PRTA / Prothena Corporation plc 3,022,222